Intratumoral Cytokine mRNA Therapy

Example 11

Mice bearing a single CT26 tumor on one flank received a four intratumoral injections of a cytokine mRNA mixture of IL-15 sushi, GM-CSF, IFNα, and IL-12sc (ModB; SEQ ID NOs: 53, 41, 59, and 47). Blood was collected 13 days after first intratumoral mRNA administration and T cells specific for the gp70 tumor antigen were quantified by flow cytometry. Frequency of T cells specific for the gp70 tumor antigen in blood were strongly increased in mice upon intratumoral injection of mRNA cytokines compared to mice that had received control RNA.

Free full text: Click here

US11865159B2. Therapeutic RNA (2024-01-09). Sanofi [FR]. Inventors: Friederike Gieseke [DE], Ugur Sahin [DE], Timothy R. Wagenaar [US], Dmitri G. Wiederschain [US], Christian Hotz [DE].

Patent 2024

Blood Cd8 t cells Cytokines Flow cytometry Gm csf Ifnα Il 15 Mice Mrna T cells Tumor Tumor antigen

Top 5 similar protocols

Variable analysis

independent variables

Intratumoral injections of a cytokine mRNA mixture of IL-15 sushi, GM-CSF, IFNα, and IL-12sc (ModB)

dependent variables

Frequency of T cells specific for the gp70 tumor antigen in blood

control variables

Mice bearing a single CT26 tumor on one flank
Blood collection 13 days after first intratumoral mRNA administration

controls

Mice that received control RNA

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!